Phocas Financial Corp. Exelixis, Inc. Transaction History
Phocas Financial Corp.
- $24.4 Billion
- Q1 2024
A detailed history of Phocas Financial Corp. transactions in Exelixis, Inc. stock. As of the latest transaction made, Phocas Financial Corp. holds 156,747 shares of EXEL stock, worth $3.52 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
156,747
Previous 293,677
46.63%
Holding current value
$3.52 Million
Previous $7.05 Million
47.2%
% of portfolio
0.02%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding EXEL
# of Institutions
459Shares Held
246MCall Options Held
1.7MPut Options Held
1.02M-
Black Rock Inc. New York, NY34.9MShares$784 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$693 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA26.7MShares$599 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.1MShares$339 Million0.56% of portfolio
-
State Street Corp Boston, MA13.1MShares$294 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $7.23B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...